Anzeige
Mehr »
Login
Freitag, 29.03.2024 Börsentäglich über 12.000 News von 687 internationalen Medien

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
160 Leser
Artikel bewerten:
(0)

U.S. Government Fails American Men in the Fight Against Prostate Cancer

Doctors Ignored on Decision to Not Support PSA Testing

WASHINGTON, Oct. 6, 2011 /PRNewswire-USNewswire/ -- Prostate cancer patients, survivors, advocates and physicians are calling for transparency as the United States Preventive Services Task Force, an independent panel appointed by the federal Department of Health and Human Services, moves to eliminate prostate cancer testing for all men.

(Logo: http://photos.prnewswire.com/prnh/20110225/ZEROLOGO)

"Today's decision of no confidence on the PSA test by the U.S. Government condemns tens of thousands of men to die this year and every year going forward if families are to believe the out-of-date evidence presented by the USPSTF," said Skip Lockwood, CEO of ZERO. "A decision on how best to test and treat for prostate cancer must be made between a man and his doctor. This decision is coming from a panel that doesn't even include a urologist or medical oncologist."

The new USPSTF guidelines rate PSA testing "D," saying there is moderate or high certainty that the service has no net benefit or that the harms outweigh the benefits. This decision contradicts prostate cancer testing recommendations from medical and professional organizations, including the National Comprehensive Cancer Network and American Urological Association.

Since the decision by the USPSTF in 2009 to change prostate cancer testing recommendations for men over the age of 75, no new research has been cited that would call for a drastic change in prostate cancer testing recommendations for all men.

Recent research confirms that the PSA test saves lives. The results of the Goteborg Randomized Population-based Prostate Cancer Screening Trial, released in July 2010, showed a 44 percent decline in prostate cancer deaths as a result of PSA testing. In this Swedish study, partially funded by the National Cancer Institute, an analysis of some 20,000 men was conducted during a 14-year period.

The PSA test and advances in treatment have led to a 40 percent reduction in prostate cancer deaths since the mid-1990s, and 90 percent of all prostate cancers are now discovered before they spread outside the gland. The survival rate is nearly 100 percent when prostate cancer is detected early, while the tumor is still localized and hasn't spread.

Based on the new recommendations, insurers are unlikely to cover PSA testing going forward. Without PSA testing, there is no mechanism for early detection of prostate cancer, leaving thousands of men vulnerable and with no option to protect their health.

About ZERO - The Project to End Prostate Cancer (www.zerocancer.org)

As ZERO - The Project to End Prostate Cancer, we commit ourselves not only to reduce prostate cancer or alleviate the pain from the disease but to end it. We see a future where all men who have been diagnosed with prostate cancer will be cured or manage their illness with good quality of life, with the support they need to minimize physical and emotional suffering and to cope effectively throughout their cancer journeys.

To accomplish our goal, we increase research funds from the federal government to find new treatments and we fund local grants to end prostate cancer through our national event series, the Great Prostate Cancer Challenge. We conduct free testing through the Drive Against Prostate Cancer mobile testing program and educate patients, families and those at risk.

Available Topic Expert: For information on the listed expert, click appropriate link.
Skip Lockwood
http://www.profnetconnect.com/skip_lockwood

SOURCE ZERO - The Project to End Prostate Cancer

Großer Dividenden-Report 2024 von Dr. Dennis Riedl
Der kostenlose Dividenden-Report zeigt ganz genau, wo Sie in diesem Jahr zuschlagen können. Das sind die Favoriten von Börsenprofi Dr. Dennis Riedl
Jetzt hier klicken
© 2011 PR Newswire
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.